Neurocrine Biosciences Inc vs iShares US Power Infrastructure ETF — how do they compare? Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B), while iShares US Power Infrastructure ETF trades at $25.47 (market cap $446.54M). The key difference: Neurocrine Biosciences Inc is far larger — about 32.2× iShares US Power Infrastructure ETF's market cap, and iShares US Power Infrastructure ETF is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and iShares US Power Infrastructure ETF for 14 Days on average.
| NBIX | POWR | |
|---|---|---|
Market Cap | $14.36B | $446.54M |
Volume | 1,237,180 | 160,852 |
Sector | Health | Sector/Thematic |
52-Week High | $185.50 | $28.22 |
52-Week Low | $123.10 | $23.20 |
Typical Hold Time | 23 Days | 14 Days |
Enterprise Value | $14.37B | — |
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.25, down 1.55% on the day, with a bearish technical signal driven by moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and has beaten EPS estimates in recent quarters. Recent news highlights pipeline progress in Prader-Willi syndrome and executive appointments.
The outlook is supported by robust analyst consensus (86.49% buy ratings) and a $204.18 price target, but risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock offers growth potential from expanding rare-disease assets, contingent on successful commercialization.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →iShares U.S. Power Infrastructure ETF seeks exposure to U.S. companies involved in power infrastructure. Its holdings may include electric utilities, transmission and distribution businesses, and electrical equipment providers.
Read more on POWR →